Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.

In patients with type 2 diabetes and albuminuria, combining an SGLT2 inhibitor, a GLP-1 receptor agonist, and the nonsteroidal MRA finerenone is projected to add several years of cardiovascular and kidney event-free survival compared with conventional care.